Iovance Biotherapeutics Reports Best-in-Class Real-World Data for Amtagvi in Advanced Melanoma

Iovance Biotherapeutics reported real-world data showing a best-in-class profile for commercial Amtagvi (lifileucel) in advanced melanoma patients. Amtagvi demonstrated a 44% confirmed objective response rate and a 73% disease control rate in 41 evaluable patients. Response rates were higher with earlier treatment, with a 52% ORR following two or fewer lines of therapy. The results support consideration of lifileucel as soon as possible after immune checkpoint inhibitor treatment.